Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 y to 31,000 €. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.
- Artificial respiration
- Cross infection
- Disease prevention
- Intensive care unit
- Ventilator-associated pneumonia
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine